Kamalabadi-Farahani Mohammad, Karimi Roqaye, Atashi Amir
Department of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mol Biol Rep. 2023 Feb;50(2):1303-1309. doi: 10.1007/s11033-022-08024-6. Epub 2022 Dec 1.
Metastasis is a devastating complication of breast cancer. Cancer relapse and metastasis are associated with cancer stem cells. CicBIRC6 is a circular RNA that is proposed to be involved in the stemness of stem cells. In breast cancer, metastatic tumor cells have higher stem cell properties. In the present study, we evaluate the expression of cicBIRC6 in these cells.
After the development of a syngeneic animal model of TNBC, primary breast cancer cells named 4T1T were isolated from the tumor mass. Highly metastatic tumor cells named 4T1B and 4T1L were isolated and expanded from brain metastasis lesions and lungs of cancerous mice respectively. Sphere formation ability in metastatic and primary tumor cells was evaluated separately. The quantitative real-time polymerase chain reaction was performed to analyze the expression of cicBIRC6 in primary and metastatic tumor cells.
Our data revealed that, sphere formation ability among metastatic tumor cells was significantly higher. Surprisingly expression of cicBIRC6 was significantly upregulated in these metastatic tumor cells. In comparison with 4T1T, cicBIRC6 was upregulated 5.7 and 3.5 times in 4T1B and 4T1L respectively.
These findings provided important insights regarding the molecular properties of metastatic tumor cells and can be used for designing a targeted therapeutic strategy in combat with these cells.
转移是乳腺癌的一种毁灭性并发症。癌症复发和转移与癌症干细胞有关。CicBIRC6是一种环状RNA,被认为与干细胞的干性有关。在乳腺癌中,转移性肿瘤细胞具有更高的干细胞特性。在本研究中,我们评估了cicBIRC6在这些细胞中的表达。
建立三阴性乳腺癌同基因动物模型后,从肿瘤块中分离出名为4T1T的原发性乳腺癌细胞。分别从癌小鼠的脑转移灶和肺中分离并扩增出高转移性肿瘤细胞4T1B和4T1L。分别评估转移性和原发性肿瘤细胞的成球能力。采用定量实时聚合酶链反应分析cicBIRC6在原发性和转移性肿瘤细胞中的表达。
我们的数据显示,转移性肿瘤细胞的成球能力明显更高。令人惊讶的是,cicBIRC6在这些转移性肿瘤细胞中的表达显著上调。与4T1T相比,cicBIRC6在4T1B和4T1L中分别上调了5.7倍和3.5倍。
这些发现为转移性肿瘤细胞的分子特性提供了重要见解,可用于设计针对这些细胞的靶向治疗策略。